What this trial means for you
This study is active, not recruiting. It is not currently taking new participants, but its results may matter for treatments you're considering. It's studying Tirzepatide, Placebo for type 1 diabetes, obesity, overweight.
What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study, ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.
The study, in the sponsor's words
The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 weeks.
Can you join? The exact criteria
Below is the verbatim eligibility text from the registry. Bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.
Full eligibility criteria (for you and your doctor)
Inclusion Criteria: * Have type 1 diabetes and on insulin treatment for at least one year prior to screening * Have an HbA1c value of 7.0% to 10.5% inclusive, at screening * Have a body mass index (BMI) of ≥25 kilograms per square meter (kg/m2) at screening * Are of stable weight for at least 90 days prior to screening and agree to not start an intensive diet or exercise program during the study Exclusion Criteria: * Have experienced two or more events requiring hospitalization due to poor glucose control (hyperglycemia or (diabetic ketoacidosis (DKA)) during the period of 180 days prior to screening and until randomization. * Have experienced one or more events of severe hypoglycemia during the period of 90 days prior to screening and until randomization. * Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema * Have had chronic or acute pancreatitis * Have used any weight loss drugs or alternative remedies, including herbal or nutritional supplements, within 90 days prior to screening
Study sites by state
California
- Sansum Diabetes Research Institute, Santa Barbara
- Care Access - Santa Clarita, Santa Clarita
Colorado
- University of Colorado Anschutz Medical Campus, Aurora
Georgia
- Atlanta Diabetes Associates, Atlanta
- Orita Clinical Research, Decatur
- North Georgia Clinical Research, Woodstock
Hawaii
- East-West Medical Research Institute, Honolulu
Idaho
- Rocky Mountain Clinical Research, Idaho Falls
Illinois
- Southern Illinois University School of Medicine, Springfield
Indiana
- Indiana University Health University Hospital, Indianapolis
Iowa
- Iowa Diabetes and Endocrinology Research Center, West Des Moines
Maryland
- Endocrine and Metabolic Consultants, Rockville
Minnesota
- HealthPartners Institute dba International Diabetes Center, Minneapolis
Mississippi
- SKY Integrative Medical Center/SKYCRNG, Ridgeland
Montana
- Boeson Research MSO, Missoula
Nevada
- Palm Research Center Tenaya, Las Vegas
- Palm Research Center Sunset, Las Vegas
New York
- Albany Medical College, Division of Community Endocrinology, Albany
- Research Foundation of SUNY - University of Buffalo, Buffalo
- NYC Research, New York
- SUNY Upstate Medical University, Syracuse
North Carolina
- Lucas Research, Inc., Morehead City
Ohio
- Care Access - Lima, Lima
Oklahoma
- Alliance for Multispecialty Research, LLC, Norman
Pennsylvania
- Suburban Research Associates, West Chester
Texas
- Texas Diabetes & Endocrinology, P.A., Austin
- Velocity Clinical Research, Dallas, Dallas
- Tekton Research, LLC., McKinney
- Medrasa Clinical Research, Wylie
Washington
- Eastside Research Associates, Redmond
- Rainier Clinical Research Center, Renton
View the official record on ClinicalTrials.gov →
Follow this trial
Get an email when our monthly digest covers enrollment changes and results for trials like this one.